Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

On Friday, Maravai Lifesciences (MRVI) hit an important technical milestone, with its Relative Strength (RS) Rating moving into the 80-plus percentile with an upgrade to 82, a rise from 79 the day before.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock’s price action over the trailing 52 weeks matches up against the rest of the market.

History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they begin their biggest runs.

Looking For Winning Stocks? Try This Simple Routine

The stock, which is on theIPO Leaders list, is not currently offering a proper buying opportunity. See if the stock goes on to form a promising consolidation that could ignite a new run. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


Top and bottom line growth moved higher in the company’s most recent quarter. Earnings were up 167%, compared to 0% in the prior report. Revenue increased from 173% to 191%. The company is expected to report its latest results on or around Jul. 28.

The biotech firm earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) and Maravai Lifesciences (MRVI) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Most Related Links :
todayprimenews Governmental News Finance News

Source link

Back to top button